Answers are grounded in this paper and cite their sources.
Demonstrates enhanced peptide stability and binding against MAT2A using aldehyde chemistry in mRNA display, highlighting its potential impact on drug design.
Display technologies discover high-affinity peptides from vast combinatorial libraries. In mRNA display, flexizyme-enabled genetic code reprogramming has become the dominant approach to extend building block diversity and improve drug-relevant properties, yet post-translational modifications (PTMs) capable of installing more uniquely constrained backbone topologies remain underexplored. Here, we introduce a PTM strategy that broadens this scope by installing an aspartyl aldehyde (X), which undergoes spontaneous Pictet–Spengler-type cyclization with proximal nucleophilic side chains to yield polycyclic α-amino-γ-lactam (pcAgl) motifs. Systematic studies define the equilibria, stereochemistry, and side-chain requirements governing pcAgl formation under biocompatible conditions. Incorporation of this chemistry into reprogrammed peptide libraries enabled direct in vitro selection of pcAgl-containing ligands against the oncology target MAT2A. The selected peptides contained structurally critical pcAgl motifs, inhibited the enzyme (best IC 50 = 9 μM), and showed improved stability in human serum. This work establishes aldehyde-mediated peptide backbone alkylation in mRNA display and showcases the value of applying chemistries traditionally not considered biocompatible to expand the chemical space of genetically encoded libraries.
No takes yet. Share an insight, caveat, or question.
Bindl et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: